Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

This is an open-label study which will be conducted at 1 to 2 sites. Subjects will be required to have a clinical diagnosis of AA, AU or AT with unilateral or bilateral loss of eyebrow hair. Subjects will apply study medication to the entire affected eyebrow(s), twice-daily for 24 weeks. Safety and tolerability will be evaluated throughout the study. The duration of the study participation is anticipated to be a maximum of 233 days.